Abstract: A cosmetic agent for dyeing keratin fibers, in particular human hair, includes at least one special non-ionic linear silicone polymer and at least one oxidation dye pre product and/or a direct dye. The use of the at least one non-ionic linear silicone polymer leads to an improved colorfulness and/or depth of shades. A corresponding packaging unit (kit of parts) and a method for dyeing keratin fibers both include the cosmetic agent. The cosmetic agent and packaging unit including the same are used for increasing the colorfulness and/or depth of shades.

Abstract: The invention relates to nail compositions comprising at least one silicone-organic polymer hybrid compound and at least one alkyd resin.

Abstract: The invention relates to nail compositions comprising at least one silicone-organic polymer hybrid compound.

Abstract: The present invention relates to a cosmetic agent for dyeing, in particular for lightening keratin fibers, in particular human hair, including at least one specific aminated silicone polymer and at least one oxidation dye intermediate and/or one direct dye, wherein the use of the at least one aminated silicone polymer leads to improved care of the keratin fibers with improved hair lightening performance. The invention further relates to a corresponding packaging unit (kit of parts) and to a method for dyeing, in particular lightening, of keratin fibers. Lastly, the invention relates to the use of the cosmetic agent according to the invention and the use of a packaging unit for producing an oxidative hair lightener for care of keratin fibers with improved lightening performance.

Abstract: A packaging unit (kit of parts) for dyeing keratin fibers and related methods. The packaging unit includes, formulated separately from one another, at least one container (C1), comprising a cosmetic agent (M1), which comprises at least one compound, selected from oxidation dye precursors, direct dyes and the mixtures thereof, and at least one aminated silicone polymer, comprising at least one structural unit of formula (I) and at least one structural unit of formula (II) where a denotes a linear or branched C4 to C8 alkyl group; and n denotes integers from 1 to 4. The kit further comprises at least one container (C2) including an oxidizing agent preparation (M2), which, in a cosmetically compatible carrier, comprises at least one oxidizing agent in a total amount of 0.5 to 15 wt. % based on the total weight of the oxidizing agent preparation.

Abstract: A shelf-stable cosmetic agent for temporarily shaping keratin fibers, and in particular human hair, having improved protection against the fading of the color of keratin fibers is provided.

Abstract: The present invention relates to a cosmetic composition, comprising: (a) at least one oil phase including at least one triglyceride oil; (b) at least one polyol phase including at least one polyol; and (c) at least one surfactant phase including at least one nonionic surfactant, wherein at least one of the phases (a), (b) and (c) is visually distinct from the other(s), and the amount of the triglyceride oil is 7.5% by weight or more, preferably 10.0% by weight or more, and more preferably 15.0% by weight or more, relative to the total weight of the composition. The cosmetic composition according to the present invention can be translucent and exhibit a warm color, in particular a shiny warm color, when mixed well, for example, when shaken by hand, and observed through normal white background light. These unique optical effects can stimulate potential consumers visually.

Abstract: The present invention relates to an anhydrous composition comprising: from 3% to 15% by weight of at least one lipophilic gelling agent; from 10% to 50% by weight of fillers including at least 5% by weight of a first filler and at least 5% by weight of a second filler different from the first; and from 40% to 85% by weight of at least one fatty phase; the weight amounts being given relative to the total weight of the composition. The composition in accordance with the invention affords comfortable anhydrous care with a soft-focus effect, i.e. it can render the skin microrelief matt and/or optically smooth, fill wrinkles, hide skin imperfections and better reflect light, while at the same time giving a pleasant feel and a novel sensory effect, that of oily care that is not greasy or tacky, with powdery transformation especially when it is applied, and with a velvety skin finish, and which allows the skin to breathe.

Abstract: A shelf-stable cosmetic agent for temporarily shaping keratin fibers, and in particular human hair, has improved protection against phase separation and has increased microbiological stability.

Abstract: A hair growth oil composition to be applied topically to the human scalp in order to encourage hair growth. The present invention accomplishes these goals through a mixture of ingredients precisely proportioned to achieve a unique chemical composition that brings about maximum results. The ingredients in the composition include coconut oil, emu oil, bhringaraj (eclipta alba), amalaki (emblica officinalis), vitamin E, and pharmaceutically acceptable excipients are described. A method of use is also disclosed.

Abstract: A shelf-stable cosmetic agent for temporarily shaping keratin fibers, and in particular human hair, having improved protection against phase separation and having increased microbiological stability is provided.

Abstract: Shelf-stable cosmetic agents for temporarily shaping keratin fibers, and in particular human hair, having improved distributability/application are provided.

Abstract: The present invention is directed to a method for evaluating cosmetic materials for their efficacy in counteracting the effects of chronic stress on skin using a stress-induced premature senescence phenotype skin model. The present invention is also concerned with compositions containing a combination of actives for blocking or reversing the biological impact of chronic stress on the skin together with actives for rebuilding epidermis so as to restore elasticity.

Abstract: A composition including a support including porous polyamide particles, having a specific surface area BET greater than or equal to 8 m2/g, Glycyrrhiza glabra root extract as a cosmetic active substance impregnated on the support. Also, cosmetic products incorporating said composition, in particular for lightening the skin. The composition may be in the form of a powder.

Abstract: Disclosed are compositions and methods for their use for reducing tumor necrosis factor alpha (TNF-?) and/or vascular endothelial growth factor (VEGF) production in skin cells by topically applying to skin in need thereof, a composition comprising an effective amount of Opuntia ficus-indica tuna, Opuntia ficus-indica nopales, or both, or extracts thereof, to reduce TNF-? or VEGF production in skin cells.

Abstract: Disclosed is a method of treating skin, the method comprising topically applying to skin in need of treatment a composition comprising Michelia figo extract, wherein the composition treats the skin condition.

Abstract: The present invention provides a topical composition comprising an extract of Pichia anomala and an extract of chicory root that contains glucosamine.

Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.

Abstract: Compositions and methods for inducing pterygium regression from visual axis/central cornea, stabilizing pterygium, treating hyperemia and symptoms in pterygium patients, and treating pterygium recurrence following pterygiectomy are disclosed. The methods include administration of a multikinase inhibitor, an antimetabolite or a combination thereof to patients in need thereof.

Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.

Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Abstract: Among others, the present invention provides a blank liposome, preparation methods thereof, and a loaded liposome including the blank liposome and an active substance. The liposomes have a membrane comprising lipids and a ginsenoside of Formula I, and may further comprise a surfactant, a heat-sensitive excipient, a pH sensitive material, or an ion additive.

Abstract: A method for preparing a liposome composition for delivering polyphenolic compounds to the target organs may include preparing a complex that contains at least one polyphenolic compound. Then, encapsulating the polyphenolic compound into a liposome composition by admixing the prepared complex with the liposome ingredients.

Abstract: A micron Taiwanofungus camphoratus liposome structure which includes a first and a second liposome shell is provided. The external radius of the first liposome shell is smaller than the internal radius of the second liposome shell, and the second liposome shell encloses the first liposome shell. A first space is defined inside of the first liposome shell, which is for containing at least a first active substance, and a second space, which is for containing at least a second active substance is defined between the inside surface of the second liposome shell and the outside surface of the first liposome shell. A plurality of cup-shaped structures is formed on the outside surface of the second liposome shell. The Taiwanofungus camphoratus liposome structure contains active substances with different effects, such that the storage and transportation of multi-active substances is improved.

Abstract: A composition for delivering a bioactive material include a porous silica nanoparticle containing pores with an average pore diameter ranging from 1 nm to 100 nm, at least one of (i) a functional group which binds to the pore surface of the porous silica nanoparticle and gives the pore surface a negative charge or a positive charge, (ii) a ligand which binds to the pore surface of the porous silica nanoparticle and specifically binds to the bioactive material, and (iii) a combination of the functional group and the ligand, and a bioactive material having a size to be accommodated within the pores of the porous silica nanoparticle, the bioactive material bound to said at least one of the functional group and the ligand bound to the pore surface of the mesoporous silica nanoparticle and accommodated within the pores of the porous silica nanoparticle.

Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu·m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu·m or less.

Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.

Abstract: Nicotine formulations and their use in therapy, for instance, in nicotine replacement therapy are described. More specifically, the technology relates to solid oral nicotine formulations comprising nicotine, a sugar-alcohol-starch coagglomerate, a sugar alcohol, xylitol, and a coating, which may be used as lozenges for administration through the oral cavity.

Abstract: The present invention specifically refers to a pharmaceutical system for preparation of solid pharmaceutical forms for administering therapeutic substances improving their bioavailability; said system is particularly suitable for administering sensitive active principles by their proteinaceous nature or by being nucleic acids since polymeric excipients with good matrix and bioadhesion properties are used which together with the impermeability conferred by the applied coating make the prepared system a delivery form with excellent performance.

Abstract: Provided are a sustained-release composition including pregabalin and a pharmaceutically acceptable salt thereof using a gastroretentive drug delivery system (GRDDS), an oral sustained-release formulation using the composition, and a preparation method thereof. In a sustained-release composition according to the present invention and a formulation including the same, a coating compartment including a sugar or a derivative thereof and a plasticizer is introduced onto the outer surface of pregabalin having a less stable structure to ensure stability and to improve compatibility with excipients at the same time, and also to effectively control the release rate. As a result, dosing convenience is improved to provide a gastroretentive drug delivery system having enhanced patient compliance. Therefore, the present invention may exhibit improved therapeutic or prophylactic effects on various neurological diseases, such as neuropathic pain, epilepsy, fibromyalgia syndrome, etc.

Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.

Abstract: Provided is a composition for preparing a soft capsule shell that includes a non-animal material, and more particularly a composition for preparing a soft capsule shell, which includes modified starch composed of modified waxy corn starch and modified waxy potato starch, thereby realizing a soft capsule shell having appropriate hardness and elastic strength and delaying a browning phenomenon. The composition includes modified starch composed of modified waxy corn starch and modified waxy potato starch at a weight ratio of 2:8 to 8:2, a modified starch hydrolysate, a gelling agent, a plasticizer and purified water.

Abstract: A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy. With respect to gene delivery, the inventive method may be used in cancer therapy, but is not limited to such use; it will be appreciated that the inventive method may be used for gene delivery in general. The controlled and precise application of thermal energy enhances gene transfer to any cell, whether the cell is a neoplastic cell, a pre-neoplastic cell, or a normal cell.

Abstract: Particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy) phosphazene] and/or a derivatives thereof which may be present throughout the particles or within an outer coating of the particles. The particles can also include a core having a hydrogel formed from an acrylic-based polymer. Barium sulfate may also be provided to the core of the particles as a coating or absorbed within the core of the particles. The particles can be used to minimize blood flow to mammalian tissues by occluding at least a portion of a blood vessel of the mammal, or to deliver an active agent to a localized area within a body of a mammal by contacting a localized area with at least one of the particles. Further, the particles are useful in sustained release formulations including active agent(s) for oral administration, as tracer particles for injection into the bloodstream of a mammal or for use in enhanced ultrasound imaging.

Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.

Abstract: This invention defines gated silica nanoparticles into which chemical cargo materials or substances are embedded and of which surfaces are coated with biologically active gating molecules and apparatus employing such silica nanoparticles. The invention and the apparatus employing the invention have the potential to be used in diverse fields such as health, food and textiles. Furthermore, the applicability of the invention and the apparatus defined in this document is not limited to the above fields and can be extended to many other sectors.

Abstract: An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at ?5 to 50° C. to introduce the drug into the empty capsid or the empty particle.

Abstract: A continuous process for the manufacture of solid lipid nanoparticles includes preparing a pre-emulsion comprising a lipid and continuously passing the pre-emulsion through a high pressure homogenizer.

Abstract: An oral delivery system (ODS) is disclosed, the oral delivery system (ODS) comprising a first compartment (FCO) and a second compartment (SCO), said first compartment (FCO) comprising a first component (FC) comprising natural unbranched polysaccharide, said second compartment (SCO) comprising a second component (SC) comprising multivalent cations, wherein the oral delivery system (ODS) is adapted for administering the first and second components (FC, SC) in a synchronized manner to the oral cavity, whereby a bioadhesive gel is formed from said natural unbranched polysaccharide and said multivalent cationsin a cross-linking reaction.

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Abstract: Orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs) comprising memantine and methods of treating conditions, including childhood behavioral disorders and Alzheimer's disease, by administering orally dissolving formulations are provided. The orally dissolving formulations of the present invention may be used to treat various conditions, but is particularly suited to treat childhood behavioral disorders, such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) and also to treat elderly patients suffering from Alzheimer's disease.

Abstract: The present invention relates to improved topical gel compositions comprising an active agent, and uses thereof.

Abstract: Methods of regulating disorders and diseases in cells expressing ?2-adrenergic receptor (AR), cannabinoid (CB) receptor and epidermal growth factor receptor (EGFR), include treating a disorder or disease, such as a melanoma include administration of a fenoterol analogue.

Abstract: Methods of regulating disorders and diseases in cells expressing ?2-adrenergic receptor (AR), cannabinoid (CB) receptor and epidermal growth factor receptor (EGFR), include treating a disorder or disease, such as a breast cancer include administration of a fenoterol analogue.

Abstract: A method of producing a biologic liquid sampling tablet is disclosed and includes molecularly imprinting a polymer over a matrix of an analyte of interest for biological testing; and removing the matrix from the imprinted polymer to form a porous tablet. The tablet is sized to be inserted in an ampoule or human oral cavity.